US5688785A
(en)
*
|
1991-07-23 |
1997-11-18 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5631365A
(en)
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
AU2943095A
(en)
*
|
1994-06-20 |
1996-01-15 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US6262277B1
(en)
*
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US5633246A
(en)
*
|
1994-11-18 |
1997-05-27 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5624920A
(en)
*
|
1994-11-18 |
1997-04-29 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5656624A
(en)
*
|
1994-12-21 |
1997-08-12 |
Schering Corporation |
4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
|
JP3023179B2
(ja)
*
|
1995-09-27 |
2000-03-21 |
シェーリング コーポレイション |
立体選択的微生物還元プロセス
|
US5843938A
(en)
*
|
1995-10-03 |
1998-12-01 |
Beiersdorf-Lilly Gmbh |
Treatment of atherosclerosis
|
EP0766962A3
(de)
*
|
1995-10-03 |
2000-05-10 |
Beiersdorf-Lilly GmbH |
Behandlung der Atherosclerose
|
EP0877750B1
(de)
*
|
1995-10-31 |
2002-06-19 |
Schering Corporation |
Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
|
WO1997016424A1
(en)
*
|
1995-11-02 |
1997-05-09 |
Schering Corporation |
Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
|
EP0939632B1
(de)
|
1996-02-23 |
2005-10-05 |
Eli Lilly And Company |
Non-peptidische vasopressin via antagonisten
|
US5739321A
(en)
*
|
1996-05-31 |
1998-04-14 |
Schering Corporation |
3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
|
US5886171A
(en)
*
|
1996-05-31 |
1999-03-23 |
Schering Corporation |
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
|
US5756470A
(en)
*
|
1996-10-29 |
1998-05-26 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
FR2762336B1
(fr)
*
|
1997-04-21 |
1999-06-11 |
Francois Trantoul |
Procede de fabrication d'un film a motif non reproductible par lecture optique pour la protection de documents
|
US6133001A
(en)
*
|
1998-02-23 |
2000-10-17 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
|
US5919672A
(en)
*
|
1998-10-02 |
1999-07-06 |
Schering Corporation |
Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
|
CA2353981C
(en)
*
|
1998-12-07 |
2005-04-26 |
Schering Corporation |
Process for the synthesis of azetidinones
|
US6207822B1
(en)
|
1998-12-07 |
2001-03-27 |
Schering Corporation |
Process for the synthesis of azetidinones
|
EP1340509A1
(de)
*
|
1998-12-23 |
2003-09-03 |
G.D. Searle LLC. |
Kombinationen von Cholesteryl-Ester-Transfer-Protein-Inhibitoren und Fibrinsäure-Derivaten für kardiovaskuläre Indikationen
|
EA200100707A1
(ru)
|
1998-12-23 |
2001-12-24 |
Джи.Ди.Сирл Ллс |
Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и производных фибриновой кислоты для сердечно-сосудистых показаний
|
PL348609A1
(en)
|
1998-12-23 |
2002-06-03 |
Searle Llc |
Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
|
IL143944A0
(en)
*
|
1998-12-23 |
2002-04-21 |
Searle Llc |
Combinations for cardiovascular indications
|
KR20010108046A
(ko)
|
1998-12-23 |
2001-12-07 |
윌리암스 로저 에이 |
심장혈관의 징후에 대한 회장 담즙산 수송 저해제 및콜레스테릴 에스테르 운반 단백질 저해제의 조합물
|
US6462091B1
(en)
|
1998-12-23 |
2002-10-08 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
|
DE69908644T2
(de)
|
1998-12-23 |
2004-05-13 |
G.D. Searle Llc, Chicago |
Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
|
US6489366B1
(en)
*
|
1998-12-23 |
2002-12-03 |
G. D. Searle, Llc |
Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
|
CN1249250C
(zh)
|
1999-04-05 |
2006-04-05 |
先灵公司 |
用于制备1-(4-氟苯基)-3(R)-[3(S)-羟基-3-(4-氟苯基)丙基]-4(S)-(4-羟苯基)-2-β丙内酰胺的立体选择性微生物还原反应
|
US6297268B1
(en)
|
1999-11-30 |
2001-10-02 |
Schering Corporation |
Imidazoles as cholesterol lowering agents
|
AU2001247331A1
(en)
*
|
2000-03-10 |
2001-09-24 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
WO2001068637A2
(en)
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Method for the preparation of tetrahydrobenzothiepines
|
US6584357B1
(en)
*
|
2000-10-17 |
2003-06-24 |
Sony Corporation |
Method and system for forming an acoustic signal from neural timing difference data
|
WO2002036124A2
(en)
*
|
2000-10-30 |
2002-05-10 |
Schering Corporation |
Treatment and method using loratadine and montelukast
|
SI1593670T1
(sl)
*
|
2000-12-20 |
2007-12-31 |
Schering Corp |
S hidroksi substituirani 2-azetidinoni, uporabni kot sredstva za zniĹľevanje holesterola
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
EP1593670B1
(de)
*
|
2000-12-20 |
2007-08-08 |
Schering Corporation |
Hydroxysubstituierte 2-Azetidinone verwendbar als Hypocholesterolemische Arzneimittel
|
EP1510521A1
(de)
*
|
2000-12-20 |
2005-03-02 |
Schering Corporation |
Zuckersubstituierte 2-Azetidinone Verwendbar als Hypocholesterdenische Arzneimittel
|
IL156552A0
(en)
*
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
RS50864B
(sr)
*
|
2000-12-21 |
2010-08-31 |
Sanofi-Aventis Deutschland Gmbh. |
Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
|
EP1911462A3
(de)
|
2001-01-26 |
2011-11-30 |
Schering Corporation |
Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
|
KR20040025889A
(ko)
*
|
2001-01-26 |
2004-03-26 |
쉐링 코포레이션 |
혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와심혈관성 제제의 조합물
|
AU2007201970B2
(en)
*
|
2001-01-26 |
2008-04-17 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
CN100522159C
(zh)
*
|
2001-01-26 |
2009-08-05 |
先灵公司 |
取代的氮杂环丁烷酮化合物在制备治疗谷甾醇血症的药物中的应用
|
IL156488A0
(en)
*
|
2001-01-26 |
2004-01-04 |
Schering Corp |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
AU2006202618B2
(en)
*
|
2001-01-26 |
2007-04-19 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
AU2008201609B8
(en)
*
|
2001-01-26 |
2009-01-08 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
AU2005246926B2
(en)
*
|
2001-01-26 |
2008-02-28 |
Merck Sharp & Dohme Corp. |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
HUP0303915A3
(en)
*
|
2001-01-26 |
2012-12-28 |
Merck Sharp & Dohme |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
MXPA03006631A
(es)
*
|
2001-01-26 |
2004-03-18 |
Schering Corp |
Combinaciones de secuestrante(s) de los acidos biliares y de inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
|
EP1671650A1
(de)
*
|
2001-01-26 |
2006-06-21 |
Schering Corporation |
Kombinationen von einem Hemmer der Sterol-Absorption und Nicotinsäure zur Behandlung von kardiovaskulären Indikationen
|
AU2006203175B2
(en)
*
|
2001-01-26 |
2008-07-24 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
TWI291957B
(en)
*
|
2001-02-23 |
2008-01-01 |
Kotobuki Pharmaceutical Co Ltd |
Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
|
KR100590342B1
(ko)
|
2001-03-28 |
2006-06-15 |
쉐링 코포레이션 |
아제티딘온 중간체 화합물의 에난티오-선택적 합성법
|
AR038956A1
(es)
*
|
2001-05-25 |
2005-02-02 |
Schering Corp |
Uso de un compuesto que regula la produccion o niveles de peptidos beta amiloides para la manufactura de un medicamento para tratar la enfermedad de alzheimer y/o para regular dichos niveles de peptidos amiloides beta en un sujeto
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
WO2003026643A2
(en)
*
|
2001-09-21 |
2003-04-03 |
Schering Corporation |
Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
|
EP1859796A3
(de)
*
|
2001-09-21 |
2008-07-02 |
Schering Corporation |
Behandlung von xanthom mit azetidinon-derivaten als hemmer der sterol absorption
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
BR0213501A
(pt)
*
|
2001-11-02 |
2004-08-24 |
Searle Llc |
Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
|
AU2002352826B2
(en)
*
|
2001-11-09 |
2009-05-28 |
Atherogenics, Inc. |
Methods of reversing and preventing cardiovascular pathologies
|
EP1465854A4
(de)
*
|
2001-12-19 |
2005-06-08 |
Atherogenics Inc |
Chalconderivate und deren verwendung zur behandlung von krankheiten
|
AU2002361811A1
(en)
|
2001-12-19 |
2003-07-09 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
FR2833842B1
(fr)
*
|
2001-12-21 |
2004-02-13 |
Aventis Pharma Sa |
Compositions pharmaceutiques a base de derives d'azetidine
|
JP2005521653A
(ja)
|
2002-01-17 |
2005-07-21 |
ファルマシア コーポレイション |
先端ナトリウム同時依存性胆汁酸輸送(asbt)およびタウロコール酸塩取込みの阻害剤としての新規アルキル/アリールヒドロキシまたはケトチエピン化合物
|
WO2003074101A1
(en)
*
|
2002-02-28 |
2003-09-12 |
Eli Lilly And Company |
Method of treating atherosclerosis and hypercholesterolemia
|
US20040116510A1
(en)
*
|
2002-03-05 |
2004-06-17 |
Nichtberger Steven A. |
Antihypertensive agent and cholesterol absorption inhibitor combination therapy
|
US20030204096A1
(en)
*
|
2002-03-25 |
2003-10-30 |
Schering Corporation |
Enantioselective synthesis of azetidinone intermediate compounds
|
DE10227508A1
(de)
*
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
GB0215579D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
EP1656368A4
(de)
*
|
2002-07-09 |
2009-08-26 |
Bristol Myers Squibb Co |
Als antidiabetika und mittel gegen obesitas geeignete substituierte heterocyclische derivate und verfahren
|
US7135556B2
(en)
*
|
2002-07-19 |
2006-11-14 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
US20040132058A1
(en)
|
2002-07-19 |
2004-07-08 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
AR040588A1
(es)
*
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
EP1545479B1
(de)
*
|
2002-07-30 |
2010-10-27 |
Karykion Inc. |
Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
|
AU2003303239A1
(en)
*
|
2002-12-19 |
2004-07-14 |
Atherogenics, Inc. |
Process of making chalcone derivatives
|
CA2517571C
(en)
*
|
2003-03-07 |
2011-07-05 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
MXPA05009501A
(es)
*
|
2003-03-07 |
2005-10-18 |
Schering Corp |
Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
MXPA05009502A
(es)
*
|
2003-03-07 |
2005-10-18 |
Schering Corp |
Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
EP1626954A2
(de)
*
|
2003-05-05 |
2006-02-22 |
Ranbaxy Laboratories, Ltd. |
Verfahren zur herstellung von trans-isomeren von diphenylazetidinonderivativen
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
EP1658283A2
(de)
*
|
2003-05-30 |
2006-05-24 |
Ranbaxy Laboratories, Ltd. |
Substituierte pyrrolderivate und deren verwendung als hmg-co-inhibitoren
|
EP1635813A4
(de)
*
|
2003-06-06 |
2009-07-01 |
Merck & Co Inc |
Kombinationstherapie zur behandlung von dyslipidämie
|
WO2005009951A2
(en)
*
|
2003-07-24 |
2005-02-03 |
Merck & Co., Inc. |
Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
|
AU2003259547A1
(en)
*
|
2003-07-31 |
2005-02-14 |
Hetero Drugs Limited |
Ezetimibe polymorphs
|
EP1522541A1
(de)
*
|
2003-10-07 |
2005-04-13 |
Lipideon Biotechnology AG |
Neue hypocholesterolemische Verbindungen
|
WO2005042692A2
(en)
*
|
2003-10-31 |
2005-05-12 |
Forbes Medi-Tech Inc. |
A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
|
EP1918000A2
(de)
|
2003-11-05 |
2008-05-07 |
Schering Corporation |
Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände
|
EP1680189A2
(de)
*
|
2003-11-05 |
2006-07-19 |
Schering Corporation |
Kombinationen von lipidmodulierenden mitteln mit substituierten azetidinonen zur behandlung von vaskularen erkrankungen
|
EA010026B1
(ru)
*
|
2003-11-10 |
2008-06-30 |
Майкробиа, Инк. |
4-биарилил-1-фенилазетидин-2-оны
|
EP1687287A1
(de)
*
|
2003-11-24 |
2006-08-09 |
Hetero Drugs Limited |
Neues verfahren für ein ezetimib-zwischenprodukt
|
CN100471835C
(zh)
*
|
2003-12-23 |
2009-03-25 |
默克公司 |
抗高胆固醇血症化合物
|
CA2550215A1
(en)
*
|
2003-12-23 |
2005-07-07 |
Astrazeneca Ab |
Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
|
GB0329778D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Astrazeneca Ab |
Chemical compounds
|
CA2553769C
(en)
*
|
2004-01-16 |
2011-01-04 |
Merck & Co., Inc. |
Npc1l1 (npc3) and methods of identifying ligands thereof
|
DK1725234T4
(en)
*
|
2004-03-05 |
2016-05-09 |
Univ Pennsylvania |
METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
US20050244367A1
(en)
*
|
2004-05-03 |
2005-11-03 |
Ilypsa, Inc. |
Phospholipase inhibitors localized in the gastrointestinal lumen
|
PT1756049E
(pt)
*
|
2004-05-21 |
2007-12-17 |
Sanofi Aventis Deutschland |
Processo para a preparação de derivados de 1,4-difenilazetidinona
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
WO2006004903A2
(en)
*
|
2004-06-28 |
2006-01-12 |
Atherogenics, Inc. |
1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
|
WO2006026273A2
(en)
*
|
2004-08-25 |
2006-03-09 |
Merck & Co., Inc. |
Method of treating atherosclerosis, dyslipidemias and related conditions
|
US20060046996A1
(en)
|
2004-08-31 |
2006-03-02 |
Kowa Co., Ltd. |
Method for treating hyperlipidemia
|
AR050631A1
(es)
*
|
2004-09-09 |
2006-11-08 |
Novartis Ag |
Combinacion de compuestos organicos
|
MX2007003732A
(es)
*
|
2004-09-29 |
2007-04-23 |
Schering Corp |
Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1.
|
CN102558075A
(zh)
|
2004-12-03 |
2012-07-11 |
先灵公司 |
作为cb1拮抗剂的取代哌嗪
|
MX2007007324A
(es)
*
|
2004-12-15 |
2007-07-09 |
Schering Corp |
Ensayos funcionales para los inhibidores de absorcion de colesterol.
|
US20130082232A1
(en)
|
2011-09-30 |
2013-04-04 |
Unity Semiconductor Corporation |
Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells
|
WO2006107936A1
(en)
*
|
2005-04-04 |
2006-10-12 |
Pontificia Universidad Catolica De Chile |
The use of ezetimibe in the prevention and treatment of cholesterol gallstones
|
TW200726746A
(en)
*
|
2005-05-06 |
2007-07-16 |
Microbia Inc |
Processes for production of 4-biphenylylazetidin-2-ones
|
EP1885378A4
(de)
*
|
2005-05-09 |
2010-10-27 |
Microbia Inc |
Metallorganische benzolphosphonat-kupplungsmittel
|
CA2608075A1
(en)
*
|
2005-05-11 |
2006-11-16 |
Microbia, Inc. |
Processes for production of phenolic 4-biphenylylazetidin-2-ones
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
EP1896135A2
(de)
*
|
2005-05-25 |
2008-03-12 |
Microbia, Inc. |
Verfahren zur herstellung von 4-(biphenylyl)azetidin-2-on-phosphonsäuren
|
EP1893222A4
(de)
*
|
2005-06-15 |
2010-07-07 |
Merck Sharp & Dohme |
Anti-hypercholesterinämische verbindungen
|
CN101243072A
(zh)
*
|
2005-06-20 |
2008-08-13 |
先灵公司 |
用作组胺h3拮抗剂的哌啶衍生物
|
CA2613239A1
(en)
*
|
2005-06-22 |
2006-12-28 |
Manne Satyanarayana Reddy |
Improved process for the preparation of ezetimibe
|
AR054482A1
(es)
*
|
2005-06-22 |
2007-06-27 |
Astrazeneca Ab |
Derivados de azetidinona para el tratamiento de hiperlipidemias
|
SA06270191B1
(ar)
*
|
2005-06-22 |
2010-03-29 |
استرازينيكا ايه بي |
مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
|
EP1741427A1
(de)
*
|
2005-07-06 |
2007-01-10 |
KRKA, D.D., Novo Mesto |
Pharmazeutische Zusammensetzung enthaltend Simvastatin und Ezetimibe
|
US20070049748A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Uppala Venkata Bhaskara R |
Preparation of ezetimibe
|
JP2008517951A
(ja)
|
2005-09-08 |
2008-05-29 |
テバ ファーマシューティカル インダストリーズ リミティド |
(3r,4s)−4−((4−ベンジルオキシ)フェニル)−1−(4−フルオロフェニル)−3−((s)−3−(4−フルオロフェニル)−3−ヒドロキシプロピル)−2−アゼチジノン、すなわちエゼチミベの合成のための中間体の調製方法
|
TW200806623A
(en)
*
|
2005-10-05 |
2008-02-01 |
Merck & Co Inc |
Anti-hypercholesterolemic compounds
|
EP2332526A3
(de)
|
2005-10-21 |
2011-10-12 |
Novartis AG |
Kombination eines Renin-Inhibitors mit einem anti-dyslipidämischen Wirkstoff oder einem Wirkstoff gegen Adipositas
|
BRPI0618379A2
(pt)
*
|
2005-11-08 |
2011-08-30 |
Ranbaxy Lab Ltd |
processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
|
HU0501164D0
(en)
*
|
2005-12-20 |
2006-02-28 |
Richter Gedeon Vegyeszet |
New industrial process for the production of ezetimibe
|
EP1962835A2
(de)
*
|
2005-12-21 |
2008-09-03 |
Schering Corporation |
Behandlung nicht alkoholinduzierter fettleber mittels cholesterinsenkenden mitteln und/oder h3-rezeptor-antagonisten oder -inversagonisten
|
WO2007119106A2
(en)
*
|
2005-12-22 |
2007-10-25 |
Medichem, S.A. |
Processes for preparing intermediate compounds useful for the preparation of ezetimibe
|
US7897601B2
(en)
|
2006-01-18 |
2011-03-01 |
Intervet, Inc. |
Cannabinoid receptor modulators
|
WO2007094480A1
(ja)
*
|
2006-02-16 |
2007-08-23 |
Kotobuki Pharmaceutical Co., Ltd. |
光学活性アルコールを製造する方法
|
WO2007100807A2
(en)
*
|
2006-02-24 |
2007-09-07 |
Schering Corporation |
Npc1l1 orthologues
|
KR20080096851A
(ko)
*
|
2006-03-06 |
2008-11-03 |
테바 파마슈티컬 인더스트리즈 리미티드 |
에제티미베 조성물
|
TW200744583A
(en)
*
|
2006-03-14 |
2007-12-16 |
Ranbaxy Lab Ltd |
Statin stabilizing dosage formulations
|
US20080032964A1
(en)
*
|
2006-04-10 |
2008-02-07 |
Kansal Vinod K |
Process for the synthesis of azetidinone
|
TW200811098A
(en)
*
|
2006-04-27 |
2008-03-01 |
Astrazeneca Ab |
Chemical compounds
|
US20070275052A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Glenmark Pharmaceuticals Limited |
Pharmaceutical compositions containing sterol inhibitors
|
BRPI0714361A2
(pt)
*
|
2006-07-14 |
2013-03-26 |
Ranbaxy Lab Ltd |
polimorfo cristalino, composiÇço farmacÊutica contendo o mesmo, mÉtodo para sua preparaÇço e mÉtodo de tratamento
|
US20080058305A1
(en)
*
|
2006-08-29 |
2008-03-06 |
Vinod Kumar Kansal |
Processes for the purification of (3R,4S)-4-(4-hydroxy-protected-phenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one
|
WO2008030382A1
(en)
*
|
2006-09-05 |
2008-03-13 |
Schering Corporation |
Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
|
JP2010503679A
(ja)
|
2006-09-15 |
2010-02-04 |
シェーリング コーポレイション |
疼痛および脂質代謝障害を処置する際に有用なアゼチジン誘導体およびアゼチドン誘導体
|
MX2009002921A
(es)
*
|
2006-09-15 |
2009-04-01 |
Schering Corp |
Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
|
JP2010503678A
(ja)
*
|
2006-09-15 |
2010-02-04 |
シェーリング コーポレイション |
アゼチジノン誘導体およびその使用方法
|
AR062790A1
(es)
*
|
2006-09-15 |
2008-12-03 |
Schering Corp |
Derivados de azetidina utiles en el tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos
|
EP2066668A1
(de)
*
|
2006-09-15 |
2009-06-10 |
Schering Corporation |
Spirozyklische azetidinon-derivate zur behandlung von fettstoffwechselkrankheiten, schmerzen, diabetes und anderen erkrankungen
|
US20080085315A1
(en)
*
|
2006-10-10 |
2008-04-10 |
John Alfred Doney |
Amorphous ezetimibe and the production thereof
|
CN100564357C
(zh)
*
|
2006-10-20 |
2009-12-02 |
浙江天宇药业有限公司 |
一种氮杂环丁酮衍生物及其合成方法
|
EP2124549A4
(de)
*
|
2006-12-20 |
2010-01-20 |
Merck & Co Inc |
Antihypercholesterinämische verbindungen
|
EP1939174A1
(de)
*
|
2006-12-21 |
2008-07-02 |
LEK Pharmaceuticals D.D. |
Einschlusskomplex von Ezetimib und einem Cyclodextrin und Verfahren zu seiner Herstellung
|
US20080161279A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Wisler Gerald L |
Methods of Treating Obesity
|
EP2125715A2
(de)
*
|
2007-01-24 |
2009-12-02 |
Krka |
Verfahren zur herstellung von ezetimib und derivaten davon
|
WO2008096372A2
(en)
*
|
2007-02-06 |
2008-08-14 |
Ind-Swift Laboratories Limited |
Process for preparing highly pure ezetimibe using novel intermediates
|
WO2008104875A1
(en)
*
|
2007-03-01 |
2008-09-04 |
Pfizer Products Inc. |
Oxazolidinones as cholesterol absorption inhibitors
|
WO2008108486A1
(ja)
|
2007-03-06 |
2008-09-12 |
Teijin Pharma Limited |
1-ビアリールアゼチジノン誘導体
|
CL2008000684A1
(es)
|
2007-03-09 |
2008-08-01 |
Indigene Pharmaceuticals Inc |
Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
|
WO2008123953A1
(en)
*
|
2007-04-02 |
2008-10-16 |
Merck & Co., Inc. |
Anti-hypercholesterolemic compound
|
WO2008130616A2
(en)
*
|
2007-04-19 |
2008-10-30 |
Schering Corporation |
Diaryl morpholines as cb1 modulators
|
US8048880B2
(en)
*
|
2007-05-03 |
2011-11-01 |
Anthera Pharmaceuticals, Inc. |
Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
|
JP2010529148A
(ja)
*
|
2007-06-07 |
2010-08-26 |
テバ ファーマシューティカル インダストリーズ リミティド |
エゼチミブ製造のための還元方法
|
US20080318920A1
(en)
*
|
2007-06-19 |
2008-12-25 |
Protia, Llc |
Deuterium-enriched ezetimibe
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
US20080319221A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
BRPI0814806A2
(pt)
*
|
2007-06-28 |
2015-02-03 |
Intervet Int Bv |
Pirazinas substituídas como antagonistas de cb1
|
CA2694264A1
(en)
*
|
2007-06-28 |
2009-01-08 |
Intervet International B.V. |
Substituted piperazines as cb1 antagonists
|
CA2694378A1
(en)
*
|
2007-07-27 |
2009-02-05 |
Cipla Limited |
Pharmaceutical compositions and process for making them
|
WO2009024889A2
(en)
|
2007-08-21 |
2009-02-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
|
US20090093627A1
(en)
*
|
2007-08-30 |
2009-04-09 |
Lorand Szabo |
Process for preparing intermediates of ezetimibe by microbial reduction
|
WO2009027785A2
(en)
*
|
2007-08-30 |
2009-03-05 |
Pfizer Products Inc. |
1, 3-oxazole derivatives as cetp inhibitors
|
DE102007063671A1
(de)
*
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
EP2965752A1
(de)
|
2007-12-10 |
2016-01-13 |
ratiopharm GmbH |
Pharmazeutische formulierung enthaltend ezetimib
|
CZ305066B6
(cs)
*
|
2008-02-25 |
2015-04-22 |
Zentiva, K.S. |
Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu
|
EP2128133A1
(de)
|
2008-05-26 |
2009-12-02 |
Lek Pharmaceuticals D.D. |
Ezetiminverfahren und -zusammensetzung
|
EP2307053A2
(de)
*
|
2008-06-06 |
2011-04-13 |
Nicox S.A. |
Zusammensetzungen mit atorvastatin 4- (nitrooxy) butylester und einem hypolipidämischen arzneimittel
|
US20090312302A1
(en)
*
|
2008-06-17 |
2009-12-17 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
|
SI2329014T1
(sl)
*
|
2008-08-29 |
2015-01-30 |
Codexis, Inc. |
Polipeptidi ketoreduktaze za stereoselektivno produkcijo (4s)-3(5s)-5(4-fluorofenil)-5-hidroksipentanoil)-4-fenil-1,3-oksazolidin -2-ona
|
MX2011005077A
(es)
|
2008-11-14 |
2011-05-25 |
Bomi P Framroze |
Un metodo para reducir el complejo de lipoproteina-beta-2-glicopro teina 1 de baja densidad oxidado circulante para el tratamiento de ateroesclerosis.
|
EP2204170A1
(de)
|
2008-12-01 |
2010-07-07 |
LEK Pharmaceuticals D.D. |
Pharmazeutische Zusammensetzung mit Ezetimibe und Simvastatin
|
EP2379562A1
(de)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Bicyclische pyranonderivate als agonisten am nicotinsäurerezeptor
|
EP2379547A1
(de)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Pyridopyrimidinderivate und verfahren zu deren anwendung
|
EP2216016A1
(de)
|
2009-02-06 |
2010-08-11 |
LEK Pharmaceuticals d.d. |
Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die Ezetimib umfasst
|
CA2754384A1
(en)
|
2009-03-06 |
2010-09-10 |
Lipideon Biotechnology Ag |
Pharmaceutical hypocholesterolemic compositions
|
ATE536172T1
(de)
|
2009-03-13 |
2011-12-15 |
Sanovel Ilac Sanayi Ve Ticaret As |
Ezetimibzusammensetzungen
|
WO2010113182A1
(en)
|
2009-03-31 |
2010-10-07 |
Lupin Limited |
Intermediates in the preparation of 1,4-diphenyl azetidinone
|
US9388440B2
(en)
|
2009-04-01 |
2016-07-12 |
Mylan Laboratories Limited |
Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
|
WO2011002424A2
(en)
|
2009-07-02 |
2011-01-06 |
Bilgic Mahmut |
Solubility and stability enchancing pharmaceutical formulation
|
WO2011019326A2
(en)
|
2009-07-02 |
2011-02-17 |
Mahmut Bilgic |
Solubility and stability enchancing pharmaceutical formulation
|
EP2448564A2
(de)
|
2009-07-02 |
2012-05-09 |
Bilgic Mahmut |
Löslichkeitsverstärkende pharmazeutische formulierung
|
CN101993403B
(zh)
*
|
2009-08-11 |
2012-07-11 |
浙江海正药业股份有限公司 |
氮杂环丁酮类化合物及医药应用
|
ES2575560T3
(es)
|
2009-08-19 |
2016-06-29 |
Codexis, Inc. |
Polipéptidos cetorreductasa para preparar fenilefrina
|
CA2790901C
(en)
|
2010-02-24 |
2018-05-01 |
Relypsa, Inc. |
Amine polymers for use as bile acid sequestrants
|
CN102858817B
(zh)
|
2010-02-24 |
2015-09-02 |
瑞立普萨公司 |
用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺
|
WO2011106545A1
(en)
|
2010-02-24 |
2011-09-01 |
Relypsa, Inc. |
Polyimidazoles for use as bile acid sequestrants
|
EP2368543A1
(de)
|
2010-03-25 |
2011-09-28 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Verfahren zur Herstellung einer granulierten pharmazeutischen Zusammensetzung mit Simvastatin und/oder Ezetimibe
|
FI3205351T3
(fi)
|
2010-04-23 |
2023-07-06 |
Alexion Pharma Inc |
Lysosomaalisen kertymätaudin entsyymi
|
WO2011140219A1
(en)
|
2010-05-04 |
2011-11-10 |
Codexis, Inc. |
Biocatalysts for ezetimibe synthesis
|
ES2372460B1
(es)
|
2010-07-09 |
2012-11-16 |
Moehs Ibérica S.L. |
Nuevo método para la preparación de ezetimiba.
|
NZ608292A
(en)
|
2010-09-09 |
2014-10-31 |
Synageva Biopharma Corp |
Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
|
DK2637646T3
(en)
|
2010-11-08 |
2016-08-29 |
Albireo Ab |
PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder
|
ME02554B
(de)
|
2010-11-08 |
2017-02-20 |
Albireo Ab |
Ibat-hemmer zur behandlung von lebererkrankungen
|
WO2012076030A1
(en)
|
2010-12-10 |
2012-06-14 |
Pharmathen S.A. |
Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
|
EP2675472A4
(de)
|
2011-02-15 |
2014-09-17 |
Synageva Biopharma Corp |
Verfahren zur behandlung von mangel an lysosomaler saurer lipase
|
US8455474B2
(en)
|
2011-03-04 |
2013-06-04 |
Mackay Memorial Hospital |
Method for treating tuberculosis
|
WO2012155932A1
(en)
|
2011-05-17 |
2012-11-22 |
Pharmathen S.A. |
Improved process for the preparation of ezetimibe
|
PL231215B1
(pl)
|
2011-06-15 |
2019-02-28 |
Inst Chemii Organicznej Polskiej Akademii Nauk |
Sposób wytwarzania podstawionych azetydynonów oraz związków pośrednich do ich syntezy
|
CN102675177A
(zh)
*
|
2011-06-28 |
2012-09-19 |
常州制药厂有限公司 |
一种降血脂药物及其关键中间体的制备方法
|
CN102952055A
(zh)
*
|
2011-08-16 |
2013-03-06 |
凯瑞斯德生化(苏州)有限公司 |
一种依泽替米贝和其中间体的制备方法
|
CN103204795B
(zh)
*
|
2012-01-11 |
2016-12-14 |
重庆华邦胜凯制药有限公司 |
一种手性氮杂环丁酮类化合物的制备方法
|
SI2844233T1
(sl)
|
2012-05-01 |
2020-08-31 |
Althera Life Sciences, Llc |
Peroralna tableta, sestavljena iz fiksne kombinacije rosuvastatina in ezetimiba za zdravljenje hiperlipidemije in bolezni srca in ožilja
|
CN103570574B
(zh)
|
2012-07-20 |
2016-04-13 |
中国科学院上海有机化学研究所 |
一种依泽替米贝的合成方法及该方法中所用的中间体
|
CN103102297A
(zh)
*
|
2012-09-28 |
2013-05-15 |
北京赛林泰医药技术有限公司 |
一种新的依折麦布的合成方法
|
TW201427658A
(zh)
|
2012-12-10 |
2014-07-16 |
Merck Sharp & Dohme |
藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
|
CN103864708A
(zh)
*
|
2012-12-12 |
2014-06-18 |
天津市医药集团技术发展有限公司 |
一种依折麦布中间体的制备方法
|
WO2015039675A1
(en)
|
2013-09-23 |
2015-03-26 |
Pharmathen S.A. |
Novel process for the preparation of ezetimibe intermediates
|
EP3065736B1
(de)
|
2013-11-04 |
2018-11-14 |
Merck Sharp & Dohme Corp. |
Glucagon-rezeptor-antagonist-verbindungen, zusammensetzungen daraus und verfahren zur verwendung
|
US9926269B2
(en)
|
2013-12-18 |
2018-03-27 |
Rudjer Boskovic Institute |
Beta-lactam cholesterol absorption inhibitors
|
CN103739537B
(zh)
*
|
2013-12-24 |
2015-05-20 |
连云港恒运医药科技有限公司 |
依折麦布的新合成方法
|
KR20150079373A
(ko)
|
2013-12-30 |
2015-07-08 |
한미약품 주식회사 |
에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
|
CN103755616A
(zh)
*
|
2013-12-31 |
2014-04-30 |
北京万全德众医药生物技术有限公司 |
一种制备依泽替米贝异构体的方法
|
ES2864079T3
(es)
|
2014-05-30 |
2021-10-13 |
Pfizer |
Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
|
CN105294426B
(zh)
*
|
2014-06-09 |
2019-05-14 |
浙江海正药业股份有限公司 |
氮杂环丁酮化合物制备方法及其中间体
|
CN104447474A
(zh)
*
|
2014-11-11 |
2015-03-25 |
武汉武药科技有限公司 |
一种依折麦布异构体的合成方法
|
CN104387308A
(zh)
*
|
2014-11-18 |
2015-03-04 |
武汉福星生物药业有限公司 |
一种控制EZ-zanOH杂质产生制备高纯度依折麦布的方法
|
CN104513187B
(zh)
*
|
2015-01-09 |
2017-05-31 |
安润医药科技(苏州)有限公司 |
依折麦布及其中间体的合成方法
|
JP2016145173A
(ja)
*
|
2015-02-09 |
2016-08-12 |
株式会社トクヤマ |
(3r,4s)‐1‐(4‐フルオロフェニル)‐[3(s)‐ヒドロキシ‐3‐(4‐フルオロフェニル)プロピル]‐(4‐ヒドロキシフェニル)‐2‐アゼチジノンの製造方法
|
CA2978204A1
(en)
|
2015-03-13 |
2016-09-22 |
Esperion Therapeutics, Inc. |
Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
CN105287513A
(zh)
*
|
2015-10-23 |
2016-02-03 |
浙江永宁药业股份有限公司 |
一种依折麦布药物组合物及其制备方法
|
CN107098841A
(zh)
*
|
2016-02-19 |
2017-08-29 |
常州方楠医药技术有限公司 |
一种依折麦布的制备方法及该方法中所用的中间体
|
WO2018103642A1
(en)
|
2016-12-05 |
2018-06-14 |
Patsnap |
Systems, apparatuses, and methods for searching and displaying information available in large databases according to the similarity of chemical structures discussed in them
|
US20180338922A1
(en)
|
2017-05-26 |
2018-11-29 |
Esperion Therapeutics, Inc. |
Fixed dose formulations
|
EP3437636A1
(de)
|
2017-08-02 |
2019-02-06 |
Adamed sp. z o.o. |
Pharmazeutische zusammensetzung mit ezetimibe
|
WO2019143707A1
(en)
|
2018-01-16 |
2019-07-25 |
Q.E.D. Environmental Systems, Inc. |
Fluid level monitoring system and method incorporating pressure sensor system having inflatable/collapsible bag
|
WO2020191163A1
(en)
|
2019-03-20 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
|
CA3133000A1
(en)
|
2019-03-20 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors
|
BR112022001783A2
(pt)
|
2019-07-31 |
2022-03-22 |
Tecnimede Soc Tecnico Medicinal Sa |
Composições orais sólidas multiunitárias de liberação imediata, seus métodos e usos.
|
EP4188338A1
(de)
|
2020-07-27 |
2023-06-07 |
KRKA, d.d., Novo mesto |
Zweischichtige tablette mit ezetimib und atorvastatin
|
CA3222897A1
(en)
*
|
2021-06-17 |
2022-12-22 |
Xufei LI |
Hybutimibe intermediate and preparation method therefor
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|